Re: Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Source: BMJ Comments - Category: General Medicine Source Type: forums
More News: Breast Cancer | Cancer | Cancer & Oncology | Docetaxel | General Medicine | HER2 | Herceptin | Taxotere